Phase 1 Study To Evaluate The Effect Of Single Doses Of Pf-05175157 On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 17 May 2012
At a glance
- Drugs PF 5175157 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 17 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 17 May 2012 Actual number of patients is 22 as reported by ClinicalTrials.gov.
- 17 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.